Stock & Company Details
Celcuity Inc $CELC
Price:
N/A
N/A
49M
$4.6B
52 Week High:
N/A
10 Day Average Volume:
N/A
-22.70
50 Day Moving Average:
N/A
52 Week Low:
N/A
30 Day Average Volume:
N/A
N/A
N/A
N/A
30 Day Change:
N/A
3 Month Change:
N/A
Commercial Services
CELC technical indicators
Latest Celcuity Inc (CELC) indicator readings as of 2026-08-28.
CELC's 14-day RSI is 44.6, in neutral territory. At $88.44 it is trading 16.6% below its 200-day moving average of $105.99, and below its 50-day average of $94.24. Price sits near the lower Bollinger Band ($87.17 to $96.03). ADX reads 14.1, indicating a range-bound market rather than a trend.
Select a strategy to see its performance
Backtested on this stock over recent history.
| Strategy | Trend | Return | Win rate |
|---|---|---|---|
| MACD Momentum Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | – | – | |
| RSI Reversal Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | – | – | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | – | – | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | – | – |
Overview
Celcuity Inc is a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications. The company's therapeutic candidate is gedatolisib, a potent, well-tolerated, small molecule dual inhibitor, administered intravenously, that selectively targets all Class I isoforms of PI3K and the mammalian target of rapamycin (mTOR).
Finance Bot
Ask your questions
Start by typing a question below.
